| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/01/2023 | 304.08% | HC Wainwright & Co. | $6 → $4 | Maintains | Buy |
| 05/30/2023 | 506.12% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 04/03/2023 | 506.12% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 03/29/2023 | 506.12% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 01/18/2022 | 506.12% | HC Wainwright & Co. | $4 → $6 | Maintains | Buy |
| 11/30/2021 | 304.08% | Maxim Group | → $4 | Initiates Coverage On | → Buy |
| 02/07/2019 | 203.06% | HC Wainwright & Co. | → $3 | Assumes | → Buy |
What is the target price for Citius Pharma (CTXR)?
The latest price target for Citius Pharma (NASDAQ: CTXR) was reported by HC Wainwright & Co. on August 1, 2023. The analyst firm set a price target for $4.00 expecting CTXR to rise to within 12 months (a possible 304.08% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Citius Pharma (CTXR)?
The latest analyst rating for Citius Pharma (NASDAQ: CTXR) was provided by HC Wainwright & Co., and Citius Pharma maintained their buy rating.
When is the next analyst rating going to be posted or updated for Citius Pharma (CTXR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Citius Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Citius Pharma was filed on August 1, 2023 so you should expect the next rating to be made available sometime around August 1, 2024.
Is the Analyst Rating Citius Pharma (CTXR) correct?
While ratings are subjective and will change, the latest Citius Pharma (CTXR) rating was a maintained with a price target of $6.00 to $4.00. The current price Citius Pharma (CTXR) is trading at is $0.99, which is out of the analyst's predicted range.